Boston | June 22–23, 2026 | Booth 205

The ISPE AI in Life Sciences Summit 2026 brings together leaders across pharma, biotech, and technology to explore how artificial intelligence is being applied across the life sciences landscape. Taking place June 22–23 in Boston, the ISPE AI in Life Sciences Summit 2026 focuses on real-world applications of AI and how teams are introducing structure, consistency, and clarity into complex processes.

Weave will be at booth 205, sharing how a human-driven approach to AI helps teams manage complex documentation across the product lifecycle. Rather than replacing human expertise, Weave supports how teams organize, author, review, verify, and publish documentation in a more structured and connected way.

At the ISPE AI in Life Sciences Summit 2026, conversations are centered around how AI fits into existing workflows. Weave aligns with this focus by bringing structure to documentation without disrupting how teams already work. From early development through postmarket, teams can maintain traceability, support structured review, and keep documentation aligned across functions.

If you are attending the ISPE AI in Life Sciences Summit 2026, stop by booth 205 to connect with our team. We’ll walk through how documentation can be organized and managed with greater clarity, helping teams stay aligned while moving work forward efficiently.

Two conversations. Two different vantage points on agentic AI in drug development.

Ari Caroline, Weave’s Co-founder and Chief Strategy Officer, will be at the AI Agent Conference on May 5, contributing to both.

2:05 PM
Agentic AI in Drug Development: From Discovery to Approval
Ari joins Saira Mueller (Morning Brew) and Umut Eser (Johnson & Johnson) to explore how agentic systems are showing up across the lifecycle—from early discovery through approval.

2:25 PM
Getting it Right: Applying Novel Agentic AI Capabilities in a High-Stake, High-Complexity Drug Development Setting
Ari will host a panel with Andrew Robertson (Takeda), Vada Perkins (Boehringer Ingelheim), and Viral Vyas (Bristol Myers Squibb), focused on what it actually takes to apply these systems in real, high-stakes environments.

From big-picture potential to practical application—both conversations stay grounded in what teams are working through right now.

---

Weave at DIA Global Annual Meeting — Booth 1218

Weave is exhibiting at DIA 2026, where we’ll be showcasing how human-driven AI supports complex, document-intensive work across regulatory and clinical teams. Stop by to see how AI helps organize and connect source information, streamline drafting and review cycles, and provide clear visibility into document evolution—while keeping subject matter experts firmly in control.

Don’t miss our talks:

Monday, June 15 | 1:05 – 1:35 PM | Track 03: Data-Tech-AI

Session Title:
The connected submission: How AI, automation, and intelligence are changing the regulatory ecosystem

Session Description:
Regulatory teams are being asked to move faster while maintaining consistency and quality across increasingly complex submissions. Disconnected authoring processes and inconsistent standards make this difficult to scale.

In this session, we explore how AI-enabled authoring, process standardization, and automation come together to support a more connected submission approach. Drawing from real-world experience, we’ll walk through how these elements can improve speed and consistency, and how connecting them enables new forms of regulatory intelligence to support more proactive planning and decision-making.

We’ll also share practical frameworks for implementing these capabilities within existing processes—what to change, what to keep, and how to approach adoption across teams.

Speakers:
Brandon Rice, CEO and Co-founder, Weave Bio
Katie Connelly, SVP, Global Head of Regulatory Affairs, Parexel

Tuesday, June 16 | 9:15 – 9:45 AM | Innovation Theater:

Session Title:
Threading AI Throughout the Drug Development Lifecycle: An Enterprise Lens

Session Description:
Enterprise pharma teams face increasing pressure to move faster while maintaining the quality and consistency required for complex health authority interactions. Fragmented workflows and evolving data make this especially challenging at scale.

In this session, we share real-world lessons from working with partners on how a unified, human-driven AI approach can support more consistent, efficient narrative development across the lifecycle. We’ll walk through key considerations for selecting, designing, and implementing AI within existing processes—along with where to adapt workflows and where to preserve them.

Speakers:
Brandon Rice, CEO and Co-founder, Weave Bio
Andrew S. Robertson, Ph.D., JD, Vice President and Head of Global Regulatory Policy & Innovation, Takeda

Weave at Festival of Biologics USA — Booth 207

Weave is exhibiting at Festival of Biologics USA at Booth 207, where we’ll be showcasing how human-driven AI supports complex, document-intensive work across drug development. Stop by to see how AI helps organize and connect source information, assist with drafting and revision, and provide clear visibility into how documents evolve—while keeping experts in control.

Don’t miss our talk on Thursday, March 5 | 11:40 AM:

Human-Driven AI for Documentation in Drug Development

Drug development teams work with complex documentation across research, development, and clinical programs. This work is often high-stakes, commonly supports regulatory progression, and always requires accuracy, consistency, and clear accountability as complexity grows.

In this session, we’ll explore how human-driven AI can be applied to support sensitive, document-centric work without removing people from the process. Using Weave’s platform as a reference point, we’ll discuss how AI can help organize and connect source information, assist with drafting and revision, and provide better visibility into how documents evolve over time.

Rather than positioning AI as a replacement for expertise, this talk focuses on how machine learning can be used to support expert judgment, even in high-consequence contexts. Attendees will gain perspective on where AI can realistically add value, how to maintain appropriate human oversight, and what it takes to apply AI responsibly to document-intensive workflows in drug development.

Speaker: Brandon Rice, CEO

Weave at the Chief Medical Officers Summit 2026

Weave is excited to be part of the largest gathering of biotech Chief Medical Officers across indications, modalities, company stages, professional experience levels and geographic locations. This is the conference to connect with peers and develop the skills needed to succeed as a biotech CMO.

Check back soon for more information on our talk!

Weave at Precision World Medicine Conference 2026

Weave’s Co-founder and CSO, Ari Caroline, will be part of the “Can AI Really Create the Next Blockbuster Drug? Closing the Loop from Discovery to Development” panel discussion on March 6, 2026 from 1:30 – 2PM in the AI Drug Discovery track.

Weave at SCOPE 2026 — Booth 525

Weave is excited to exhibit at SCOPE 2026 at Booth 525, where we’ll be showcasing how AI and automation support more efficient, human-driven regulatory workflows across clinical development. Stop by to meet the team and see how Weave reduces manual effort and improves consistency across regulatory document creation.

Don’t miss our talk on Wednesday, February 4 | 11:15 AM :

Clinical submissions by the numbers: quantifying the workflow impact of AI

Regulatory teams often operate with lean resources while facing increasing pressure to move quickly into early-stage clinical development. This session will highlight how Weave’s AI-native, human-driven platform uses automation to significantly reduce the manual burden of creating clinical-ready regulatory documents. By structuring information, auto-generating content, and providing real-time workflow visibility, Weave helps teams accelerate document development with greater consistency and fewer repetitive tasks. The session will also incorporate insights from Weave’s work with Parexel, illustrating how AI-enabled automation can streamline real-world regulatory workflows. Attendees will gain practical strategies for applying AI and automation to speed document preparation while allowing teams to stay focused on scientific and clinical decision-making.roving workflow visibility.

Speaker: Brandon Rice, CEO

Weave at DIA RSIDM 2026 – Booth #100

Weave is proud to be a sponsor at DIA Regulatory Submissions, Information, and Document Management (RSIDM) Forum 2026, taking place February 2-4, 2026 in Bethesda, Maryland. Visit us at our booth to connect with the team and see how Weave supports more fluid, human-driven regulatory workflows for development teams across the industry.

Don’t miss our talk: February 3, 2026 10:05 – 10:35 AM

Human + AI — Weave + Parexel: Revolutionary Collaborations in 2026

Regulatory teams face increasing pressure to deliver high-quality, submission-ready documents on tight timelines, yet many processes still rely on manual, repetitive steps that slow progress and introduce inconsistencies. Brandon’s session will explore how Weave’s AI-native, human-driven platform applies automation to streamline key aspects of regulatory document development—from structuring source information to auto-generating content and improving workflow visibility.

Drawing on Weave’s work with Parexel, this case study will illustrate how automation can support real-world regulatory workflows, reduce manual effort, and improve consistency across documents. Attendees will gain practical guidance on modern, AI-enabled approaches that help teams work more efficiently and achieve more predictable timeline outcomes while maintaining the centrality of human expertise.

Featured Topics Include:
• Applying AI and automation to reduce manual effort in regulatory document development
• Using structured information and auto-generated content to improve consistency and accuracy
• Enhancing workflow visibility and predictability for IND, CTA, and other key submissions
• Real-world learnings from Weave’s collaboration with Parexel
• Practical strategies for integrating human-driven AI into regulatory operations

Presenter: Brandon Rice, CEO

Meet Weave at J.P. Morgan 2026

Weave’s CEO, Brandon Rice, and Vice President of Sales, Mark Hober will be in San Francisco for the J.P. Morgan Healthcare Conference 2026, connecting with leaders across biotech, pharma, and the broader life sciences ecosystem.

Brandon will be featured at two key industry events during JPM week:

• January 12: Biotech Dealmaking – Regulatory Considerations for the Next Wave of Development-Stage Transactions, a Sidley Global Life Sciences–sponsored event
• January 14: Goodwin and KPMG Panel

If you’re interested in discussing how teams can work more fluidly across regulatory workflows or want to learn more about Weave, you can book time directly with them here:
👉 https://calendly.com/meetwithweave/30min

We’re excited to share that Weave will be both exhibiting and speaking at the AI Drug Discovery & Development Summit, taking place November 18–20, 2025, in Boston, MA. This summit brings together leaders from biotech, pharma, and AI to explore how artificial intelligence is reshaping every stage of the drug development pipeline.

As an exhibitor, Weave will showcase how our AI-native platform supports regulatory teams in developing documents more efficiently and with greater transparency across programs. Whether drafting a new IND or updating a module for a global submission, Weave helps teams write with confidence, stay aligned, and reduce duplication of effort.

We’ll also be joining the speaker lineup to share how teams are using Weave to bring clarity and speed to their regulatory workflows. Stay tuned for talk details and booth info—we’ll share those soon.

Join us in Boston to connect with our team and see how Weave is powering the next era of regulatory writing.
Visit the event page for more information and registration.